Skip navigation

Charles River Laboratories Expands Services for Early Discovery Screening

15 May 2018

harles River Laboratories International, Inc. (NYSE: CRL) announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America andEurope. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.

Early screening provides important insight into a compound’s underlying biology, and streamlined HT-ADME and PK technologiesare essential components to identifying promising candidates early in the drug discovery process.

Addition of Apricot Designs’ ADDA System

The ADDA system is a high-speed autosampler designed for drug discovery that provides ADME discovery scientists with a fast sample delivery platform for liquid chromatography/mass spectrometry (LC/MS). Automated permeability, metabolic stability, and protein binding screening assays can be rapidly turned around with the ADDA system and a single mass spectrometer system, saving critical time in the drug discovery process.

Expansion of Pharmacokinetic Capabilities

In both San Francisco and 's-Hertogenbosch, The Netherlands, Charles River has expanded capabilities and capacity for PK screening, providing for interactive and collaborative relationships aimed at accelerating clients’ discovery programs.

Therapeutic-area-agnostic PK services support drug discovery efforts from the initial PK screening of compounds and lead optimization to late-stage candidate nomination and Investigational New Drug-enabling studies.